Cholangiocarcinoma News and Research

RSS

Patient-specific "organ-on-chip" aims to accelerate research on cholangiocarcinoma

It is only a few centimeters in size and can be held between two fingers, but in the micro-channels carved inside it, it's hidden a three-dimensional and highly faithful model of a biliary tract cancer called cholangiocarcinoma, complete with its tumor microenvironment.

22 Jan 2024

Insilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors

Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM8001, a novel molecule targeting FGFR2/3 for the treatment of tissue-agnostic solid tumors bringing the total number of PCCs nominated in 2023 to six.

28 Dec 2023

Novel miRNA-based therapy shows promise for treatment of drug-resistant biliary tract cancer

Biliary tract cancers (BTCs) including cholangiocarcinoma (CCA) and gallbladder cancer (GBC) are becoming more prevalent globally.

30 Nov 2023

Study sheds light on the complex relationship between serum lipids, lipid-modifying targets, and cholelithiasis

A new study published in the journal Gut has shed light on the complex relationship between serum lipids, lipid-modifying targets, and cholelithiasis, a common condition characterized by the formation of gallstones.

27 Nov 2023

Could the microbiome hold the key to diagnosing and treating biliary tract cancer?

A recent study in "Microorganisms" delves into the relationship between the microbiome and biliary tract cancer, revealing distinct microbial compositions in patients compared to healthy individuals. This research highlights potential diagnostic biomarkers and suggests that altering gut microbial composition might enhance responses to cancer immunotherapy.

24 Oct 2023

Molecular insights: Detecting gene fusions offers new avenues for advanced cancer management

Study identifies gene fusions to understand their relationship with observed pathologies in cancer patients.

8 Aug 2023

Clinical trials demonstrate positive results from targeted therapy for patients with multiple tumor types with FGFR alterations

Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated positive results from the targeted therapy erdafitinib for patients with multiple tumor types harboring FGFR alterations.

5 Jun 2023

Specific enzyme produced in liver cancer cells could turn a molecule into potential anticancer drug

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead to the development of a new class of anticancer drugs.

14 Mar 2023

New insights on bile duct and gallbladder cancers

Bile duct and gallbladder cancers are uncommon, with an estimated 12,130 new cases diagnosed this year according to the American Cancer Society.

30 Jan 2023

Addition of nab-paclitaxel to gemcitabine/cisplatin does not improve overall survival of patients with advanced biliary tract cancers

Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit for subsets of patients with locally advanced disease or gallbladder adenocarcinoma.

20 Jan 2023

Modified CEUS criteria using perfluorobutane can help diagnose high-risk hepatocellular carcinoma

According to an accepted manuscript published in ARRS' American Journal of Roentgenology (AJR), diagnostic performance of LR-5 for hepatocellular carcinoma (HCC) diagnosis was not significantly different between modified contrast-enhanced ultrasound (CEUS) using perfluorobutane and CT/MRI LI-RADS version 2018.

16 Nov 2022

Scientists identify new driver for rare type of liver cancer

Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Hebrew University in Jerusalem have identified in mice the cell of origin of combined liver/biliary duct carcinomas, a rare type of cancer of the liver.

19 Aug 2022

Potential applications of bioactive molecules present in fruit peels

A recent study published in Current Issues in Molecular Biology reviewed the potential biological applications of fruit peel extracts.

13 Jun 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

Phase 2/3 study of oral RHB-107 in non-hospitalized COVID-19 patients shows promising results

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced positive top-line results from the Phase 2 part of the Phase 2/3 study of once-daily oral RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients, predominantly conducted in the U.S. (60/61 patients) as well as South Africa.

1 Mar 2022

Using interdisciplinary approach to beat cancer

European Cooperation in Science and Technology (COST) World Cancer Day aims at raising awareness of cancer and to encourage its prevention, detection, and treatment.

4 Feb 2022

ASTRO provides new guidance on the use of external beam radiation therapy for primary liver cancers

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary liver cancers using external beam radiation therapy (EBRT).

12 Jan 2022

Washington University School of Medicine receives $17 million to address disparities in cancers

Washington University School of Medicine in St. Louis has received a $17 million grant from the National Institutes of Health to address disparities in cancer research, treatment and outcomes in underrepresented populations.

6 Nov 2021

Scientists turn into molecular detectives to find clues to why certain cancer therapies stop working

A new research study at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) turns cancer scientists into molecular detectives, searching for clues for why certain cancers are able to spread and evolve by studying tissues collected within hours of death.

29 Sep 2021

Study identifies actionable genes and candidate drugs in biliary tract cancer using a knowledgebase

Oncotarget published "Actionability evaluation of biliary tract cancer by genome transcriptome analysis and Asian cancer knowledgebase" which reported that it is necessary to investigate actionable genes and candidate drugs using a sophisticated knowledgebase and characterize BTCs immunologically for evaluating the actionability of molecular and immune therapies.

31 Aug 2021